Skip to content
Menu

Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1100

Benzinga Newsdesk 2 weeks ago

Analyst RatingsNewsPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Guggenheim analyst Yatin Suneja maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $1030 to $1100.

Guggenheim analyst Yatin Suneja maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $1030 to $1100.

Read at benzinga.com

← All stock news